BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 34296548)

  • 1. Efficacy of Seven-Day Potassium-Competitive Acid Blocker-Based First-Line
    Kim JY; Lee SY; Kim H; Kim JH; Sung IK; Park HS
    Yonsei Med J; 2021 Aug; 62(8):708-716. PubMed ID: 34296548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy.
    Zhang W; Chen Q; Liang X; Liu W; Xiao S; Graham DY; Lu H
    Gut; 2015 Nov; 64(11):1715-20. PubMed ID: 26338726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 7-day versus 14-day tegoprazan-based triple therapy to treat Helicobacter pylori infection: Real-world evidence.
    Jung YS; Kim S; Kim HY; Noh SJ; Park JH; Park CH
    J Gastroenterol Hepatol; 2022 Oct; 37(10):1911-1918. PubMed ID: 35816283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triple Therapy-Based on Tegoprazan, a New Potassium-Competitive Acid Blocker, for First-Line Treatment of
    Choi YJ; Lee YC; Kim JM; Kim JI; Moon JS; Lim YJ; Baik GH; Son BK; Lee HL; Kim KO; Kim N; Ko KH; Jung HK; Shim KN; Chun HJ; Kim BW; Lee H; Kim JH; Chung H; Kim SG; Jang JY
    Gut Liver; 2022 Jul; 16(4):535-546. PubMed ID: 35791797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter, randomized, prospective study of 14-day ranitidine bismuth citrate- vs. lansoprazole-based triple therapy for the eradication of Helicobacter pylori in dyspeptic patients.
    Avşar E; Tiftikçi A; Poturoğlu S; Erzin Y; Kocakaya O; Dinçer D; Yıldırım B; Güliter S; Türkay C; Yılmaz U; Onuk MD; Bölükbaş C; Ellidokuz E; Bektaş A; Taşan G; Aytuğ N; Ateş Y; Kaymakoğlu S
    Turk J Gastroenterol; 2013; 24(4):316-21. PubMed ID: 24254262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of tegoprazan-based bismuth quadruple therapy compared with bismuth quadruple therapy for Helicobacter pylori infection: A randomized, double-blind, active-controlled study.
    Kim JS; Ko W; Chung JW; Kim TH
    Helicobacter; 2023 Jun; 28(3):e12977. PubMed ID: 37083222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy of two-week quadruple first-line therapy with bismuth, lansoprazole, amoxicillin, clarithromycin on Helicobacter pylori eradication: a prospective study.
    Ergül B; Doğan Z; Sarikaya M; Filik L
    Helicobacter; 2013 Dec; 18(6):454-8. PubMed ID: 24011287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative study of 14-day dual therapy (esomeprazole and amoxicillin four times daily) and triple plus bismuth therapy for first-line Helicobacter pylori infection eradication: A randomized trial.
    Song Z; Zhou L; Xue Y; Suo B; Tian X; Niu Z
    Helicobacter; 2020 Dec; 25(6):e12762. PubMed ID: 33040439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
    Liou JM; Fang YJ; Chen CC; Bair MJ; Chang CY; Lee YC; Chen MJ; Chen CC; Tseng CH; Hsu YC; Lee JY; Yang TH; Luo JC; Chang CC; Chen CY; Chen PY; Shun CT; Hsu WF; Hu WH; Chen YN; Sheu BS; Lin JT; Wu JY; El-Omar EM; Wu MS;
    Lancet; 2016 Nov; 388(10058):2355-2365. PubMed ID: 27769562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication.
    Sun Q; Liang X; Zheng Q; Liu W; Xiao S; Gu W; Lu H
    Helicobacter; 2010 Jun; 15(3):233-8. PubMed ID: 20557366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy.
    Song Z; Zhou L; Zhang J; He L; Bai P; Xue Y
    Dig Liver Dis; 2016 May; 48(5):506-511. PubMed ID: 26847964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing first line 7-day standard triple therapy for Helicobacter pylori eradication: Prolonging treatment or adding bismuth: which is better?
    Leow AH; Azmi AN; Loke MF; Vadivelu J; Graham DY; Goh KL
    J Dig Dis; 2018 Nov; 19(11):674-677. PubMed ID: 30307122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Tolerability of 14-Day Tegoprazan- versus Rabeprazole-Based Triple Therapy for Eradication of
    Jung YS; Kim S; Kim HY; Noh SJ; Park JH; Sohn CI; Park CH
    Gut Liver; 2023 Sep; 17(5):711-721. PubMed ID: 36510776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized trial of lansoprazole, amoxycillin, and clarithromycin versus lansoprazole, bismuth, metronidazole and tetracycline in the retreatment of patients failing initial Helicobacter pylori therapy.
    Magaret N; Burm M; Faigel D; Kelly C; Peterson W; Fennerty MB
    Dig Dis; 2001; 19(2):174-8. PubMed ID: 11549829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Twice-daily intake of bismuth-based quadruple therapy for first-line Helicobacter pylori eradication: A retrospective study on 10-day, 14-day, and half-dose antibiotic therapy.
    Lee SY; Kim JH; Sung IK; Park HS
    Helicobacter; 2023 Aug; 28(4):e12998. PubMed ID: 37293999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of bismuth added to standard triple therapy as the first-line eradication regimen for Helicobacter pylori infection.
    Kim YJ; Chung WC; Kim DB
    Helicobacter; 2021 Jun; 26(3):e12792. PubMed ID: 33650225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High efficacy of ranitidine bismuth citrate, amoxicillin, clarithromycin and metronidazole twice daily for only five days in Helicobacter pylori Eradication.
    Gisbert JP; Marcos S; Gisbert JL; Pajares JM
    Helicobacter; 2001 Jun; 6(2):157-62. PubMed ID: 11422472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved eradication rate of standard triple therapy by adding bismuth and probiotic supplement for Helicobacter pylori treatment in Thailand.
    Srinarong C; Siramolpiwat S; Wongcha-um A; Mahachai V; Vilaichone RK
    Asian Pac J Cancer Prev; 2014; 15(22):9909-13. PubMed ID: 25520127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ten-day high-dose proton pump inhibitor triple therapy versus sequential therapy for Helicobacter pylori eradication.
    Auesomwang C; Maneerattanaporn M; Chey WD; Kiratisin P; Leelakusolwong S; Tanwandee T
    J Gastroenterol Hepatol; 2018 Nov; 33(11):1822-1828. PubMed ID: 29804294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triple or quadruple tetracycline-based therapies versus standard triple treatment for Helicobacter pylori treatment.
    Songür Y; Senol A; Balkarli A; Baştürk A; Cerçi S
    Am J Med Sci; 2009 Jul; 338(1):50-3. PubMed ID: 19474657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.